- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT05798845
The Effect of Toripalimab Plus Radiotherapy in Patients With Operable Stage II-IIIA (N+) Non Small Cell Lung Cancer
April 2, 2023 updated by: Xiaolong Fu, Shanghai Chest Hospital
Exploratory Phase II Clinical Study of Toripalimab Plus Radiotherapy Versus Toripalimab Plus Chemotherapy for the Neoadjuvant Treatment of Operable Stage II-IIIA (N+) Non-small Cell Lung Cancer (NSCLC)
This randomized phase II trial is to explore the clinical efficacy, safety and feasibility of neoadjuvant immunotherapy plus radiotherapy compared with neoadjuvant immunotherapy plus chemotherapy in operable stage II-IIIA (N+) non small cell lung cancer (NSCLC) and the optimal radiotherapy pattern.
Study Overview
Status
Recruiting
Conditions
Intervention / Treatment
Detailed Description
In recent years, the survival rate after diagnosis of non small cell lung cancer (NSCLC) has improved with advances in treatment.
In terms of 5-year average overall survival (OS) by stage at the time of diagnosis, OS decreases significantly from stage IB to IIIA NSCLC, with 68% for stage IB, 53-60% for stage II, and 36% for stage IIIA.
How to optimize the perioperative treatment strategy to reduce postoperative recurrence and prolong the survival of patients has raised great concern in early and mid-stage NSCLC.
Radiotherapy combined with immunotherapy is suggested for advanced NSCLC in preclinical basic studies and recent clinical trials.
Stereotactic body radiation therapy (SBRT) at 8 Gy × 3 Fx plays an effective immunoregulated role and can further enhance the antitumor immune response promoted by immune checkpoint inhibitors (ICIs).
Although little is known about the optimal SBRT dose and fraction pattern, 6 Gy × 5 Fx or 8-9 Gy × 3 Fx have shown effectiveness in clinical studies.
Study Type
Interventional
Enrollment (Anticipated)
124
Phase
- Phase 2
Contacts and Locations
This section provides the contact details for those conducting the study, and information on where this study is being conducted.
Study Contact
- Name: Xiaolong Fu, MD
- Phone Number: 3202 862122200000
- Email: xlfu1964@126.com
Study Contact Backup
- Name: Wen Feng, MD
- Phone Number: 3203 862122200000
- Email: fengwen412@126.com
Study Locations
-
-
Shanghai
-
Shanghai, Shanghai, China, 200030
- Recruiting
- Shanghai Chest Hospital
-
Principal Investigator:
- Wentao Fang
-
Contact:
- Xiaolong Fu, MD
- Phone Number: 3202 021-22200000
-
Principal Investigator:
- Xiaolong Fu
-
-
Participation Criteria
Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.
Eligibility Criteria
Ages Eligible for Study
18 years to 75 years (Adult, Older Adult)
Accepts Healthy Volunteers
No
Genders Eligible for Study
All
Description
Inclusion Criteria:
- Age 18 to 75 years old, gender is not limited.
- ECOG performance status 0-1.
- non-small cell lung cancer diagnosed by pathology.
- sufficient tumor tissue available for biomarker analysis.
- clinical staging of cT1-2N1-2M0 or T3N1M0, stage II-IIIA (8th UICC staging criteria).
- Patients with distant metastases ruled out by CT or PET/CT and physically assessed as acceptable for radical lung cancer surgery.
- histomolecular pathology confirming the absence of classic driver oncogene mutations in EGFR, ALK, or ROS1.
Basic normal function of all organs (laboratory test results within 1 week prior to enrollment).
- Bone marrow function: absolute neutrophil count (ANC) ≥ 1.5x109 /L, platelet count ≥ 100x109 /L, hemoglobin ≥ 9g/dL.
- Liver: serum total bilirubin ≤ 1.5 times the upper limit of normal; ALT and AST ≤ 2.5 times the upper limit of normal.
- Kidney: blood creatinine level ≤ 1.5 times the upper limit of normal or creatinine clearance ≥ 60 ml/min and urea nitrogen ≤ 200 mg/L.
- Urine protein <+, if urine protein + then total 24 hour protein must be <500mg.
- Blood glucose: within normal range and/or with diabetic patients on treatment but with stable blood glucose control.
- Pulmonary function: baseline FEV1 of at least 2L; if baseline FEV1 < 2L then FEV1 > 800ml is expected after surgery as assessed by a surgical specialist.
- Cardiac function: no myocardial infarction within 1 year; no unstable angina; no symptomatic severe arrhythmia; no cardiac insufficiency.
- Voluntarily participated in this study and signed the informed consent form by himself or his agent
Exclusion Criteria:
- Pathology suggestive of compound small cell lung cancer, etc.
- History of previous lobectomy, radiotherapy or chemotherapy.
- Those with concurrent second primary carcinoma and a history of previous malignancy of less than 5 years (except for completely cured cervical carcinoma in situ or basal cell or squamous epithelial cell skin cancer).
- Patients with any active autoimmune disease or a history of autoimmune disease (e.g., interstitial pneumonia, uveitis, enterocolitis, hepatitis, pituitary inflammation, vasculitis, myocarditis, nephritis, hyperthyroidism, hypothyroidism, etc.).
- Have an active infection requiring systemic treatment or a history of active tuberculosis.
- Known history of human immunodeficiency virus (HIV) or active chronic Hepatitis C or Hepatitis B virus infection or any uncontrolled active systemic infection requiring intravenous (iv) antimicrobial treatment.
- Those with known presence or coexistence of other uncontrollable diseases that are not amenable to surgical treatment
- Physical examination or clinical trial finds that, in the opinion of the investigator, may interfere with the results or place the patient at increased risk for treatment complications
- Prior interstitial lung disease, drug-induced interstitial disease or any clinically evident active interstitial lung disease with idiopathic pulmonary fibrosis on baseline CT scan; uncontrolled massive pleural or pericardial effusion
- Unstable systemic concomitant disease (active infection, moderate to severe chronic obstructive pulmonary disease, poorly controlled hypertensive disease, unstable angina pectoris, congestive heart failure, myocardial infarction occurring within 6 months, severe mental disorder requiring medication for control, liver, renal or other metabolic disease, neuropsychiatric pathology such as Alzheimer's disease)
- History of congenital or acquired immunodeficiency disorders or organ transplantation
Received any of the following treatments:
- Prior radiotherapy, treatment with anti PD-1, anti PD-L1 or anti PD-L2 drugs, or other drugs that synergistically inhibit T-cell receptors such as CTLA-4, OX-40, CD137.
- Having received any investigational drug within 4 weeks
- Concurrent enrollment in another clinical study, unless it is an observational (non-interventional) clinical study or an interventional clinical study follow-up
- Persons who have received an antineoplastic vaccine or who have received a live vaccine within 4 weeks
- Have undergone major surgery or had severe trauma within 4 weeks
Study Plan
This section provides details of the study plan, including how the study is designed and what the study is measuring.
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: Randomized
- Interventional Model: Parallel Assignment
- Masking: None (Open Label)
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Experimental: Experimental: Arm A
Radiation: primary tumor SBRT, DT: 24Gy/3Fx, d1-3, d22-24; positive lymph nodes LDRT, DT: 2Gy/4Fx, d1-4, d22-25 (2 cycles) ; Drug: toripalimab 240mg ivgtt d5, d26 (2 cycles)
|
primary tumor SBRT, DT: 24Gy/3Fx, d1-3, d22-24; positive lymph nodes LDRT, DT: 2Gy/4Fx, d1-4, d22-25 (2 cycles)
toripalimab 240mg ivgtt d5, d26 (2 cycles)
toripalimab 240mg ivgtt d1, d22 (2 cycles)
|
Active Comparator: Conrol: Arm B
Drug: Chemotherapy + toripalimab 240mg ivgtt d1, d22 (2 cycles) Chemotherapy regimen: Non-squamous carcinoma: pemetrexed + platinum or paclitaxel + platinum. Squamous carcinoma: paclitaxel + platinum or gemcitabine + platinum |
toripalimab 240mg ivgtt d5, d26 (2 cycles)
toripalimab 240mg ivgtt d1, d22 (2 cycles)
Non-squamous carcinoma: pemetrexed + platinum or paclitaxel + platinum Squamous carcinoma: paclitaxel + platinum or gemcitabine + platinum
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Pathlogical complete remission (pCR) rate
Time Frame: 1 year
|
Pathlogical complete remission rate
|
1 year
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
major pathologic response (MPR) of primary tumor
Time Frame: 1 year
|
proportion of residual tumor ≤10%
|
1 year
|
Perioperative complications
Time Frame: 1 year
|
complications occurring during operation
|
1 year
|
Completion of surgery
Time Frame: intraoperative
|
whether the surgery is completed
|
intraoperative
|
Rate of R0 resection
Time Frame: 1 year
|
rate of participants with tumor margin negative
|
1 year
|
treatment emergent adverse event (TEAE)
Time Frame: 1 year
|
number of participants who have adverse events occurring during the treatment period
|
1 year
|
Event-free survival (EFS)
Time Frame: 3 years
|
Event-free survival
|
3 years
|
Overall survival (OS)
Time Frame: 3 years
|
Overall survival
|
3 years
|
circulating tumor DNA (ctDNA)
Time Frame: 1 year
|
the expression of circulating tumor DNA
|
1 year
|
Immune subtypes
Time Frame: 1 year
|
the tumor immune microenvironment subtype according to PD-L1 and tumor-infiltrating lymphocytes
|
1 year
|
PD-L1 expression
Time Frame: 1 year
|
the status of PD-L1
|
1 year
|
Tumor mutation burden (TMB)
Time Frame: 1 year
|
frequency of tumor gene mutation
|
1 year
|
Collaborators and Investigators
This is where you will find people and organizations involved with this study.
Sponsor
Collaborators
Publications and helpful links
The person responsible for entering information about the study voluntarily provides these publications. These may be about anything related to the study.
General Publications
- Demaria S, Coleman CN, Formenti SC. Radiotherapy: Changing the Game in Immunotherapy. Trends Cancer. 2016 Jun;2(6):286-294. doi: 10.1016/j.trecan.2016.05.002.
- Bernstein MB, Krishnan S, Hodge JW, Chang JY. Immunotherapy and stereotactic ablative radiotherapy (ISABR): a curative approach? Nat Rev Clin Oncol. 2016 Aug;13(8):516-24. doi: 10.1038/nrclinonc.2016.30. Epub 2016 Mar 8.
- Vanpouille-Box C, Alard A, Aryankalayil MJ, Sarfraz Y, Diamond JM, Schneider RJ, Inghirami G, Coleman CN, Formenti SC, Demaria S. DNA exonuclease Trex1 regulates radiotherapy-induced tumour immunogenicity. Nat Commun. 2017 Jun 9;8:15618. doi: 10.1038/ncomms15618.
- Howlader N, Forjaz G, Mooradian MJ, Meza R, Kong CY, Cronin KA, Mariotto AB, Lowy DR, Feuer EJ. The Effect of Advances in Lung-Cancer Treatment on Population Mortality. N Engl J Med. 2020 Aug 13;383(7):640-649. doi: 10.1056/NEJMoa1916623.
- Rami-Porta R, Bolejack V, Crowley J, Ball D, Kim J, Lyons G, Rice T, Suzuki K, Thomas CF Jr, Travis WD, Wu YL; IASLC Staging and Prognostic Factors Committee, Advisory Boards and Participating Institutions. The IASLC Lung Cancer Staging Project: Proposals for the Revisions of the T Descriptors in the Forthcoming Eighth Edition of the TNM Classification for Lung Cancer. J Thorac Oncol. 2015 Jul;10(7):990-1003. doi: 10.1097/JTO.0000000000000559.
- Ko EC, Raben D, Formenti SC. The Integration of Radiotherapy with Immunotherapy for the Treatment of Non-Small Cell Lung Cancer. Clin Cancer Res. 2018 Dec 1;24(23):5792-5806. doi: 10.1158/1078-0432.CCR-17-3620. Epub 2018 Jun 26.
- Wang Y, Liu ZG, Yuan H, Deng W, Li J, Huang Y, Kim BYS, Story MD, Jiang W. The Reciprocity between Radiotherapy and Cancer Immunotherapy. Clin Cancer Res. 2019 Mar 15;25(6):1709-1717. doi: 10.1158/1078-0432.CCR-18-2581. Epub 2018 Nov 9.
- Theelen WSME, Chen D, Verma V, Hobbs BP, Peulen HMU, Aerts JGJV, Bahce I, Niemeijer ALN, Chang JY, de Groot PM, Nguyen QN, Comeaux NI, Simon GR, Skoulidis F, Lin SH, He K, Patel R, Heymach J, Baas P, Welsh JW. Pembrolizumab with or without radiotherapy for metastatic non-small-cell lung cancer: a pooled analysis of two randomised trials. Lancet Respir Med. 2021 May;9(5):467-475. doi: 10.1016/S2213-2600(20)30391-X. Epub 2020 Oct 20. Erratum In: Lancet Respir Med. 2021 Mar;9(3):e29.
- Altorki NK, McGraw TE, Borczuk AC, Saxena A, Port JL, Stiles BM, Lee BE, Sanfilippo NJ, Scheff RJ, Pua BB, Gruden JF, Christos PJ, Spinelli C, Gakuria J, Uppal M, Binder B, Elemento O, Ballman KV, Formenti SC. Neoadjuvant durvalumab with or without stereotactic body radiotherapy in patients with early-stage non-small-cell lung cancer: a single-centre, randomised phase 2 trial. Lancet Oncol. 2021 Jun;22(6):824-835. doi: 10.1016/S1470-2045(21)00149-2. Epub 2021 May 18.
Study record dates
These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.
Study Major Dates
Study Start (Actual)
February 20, 2023
Primary Completion (Anticipated)
February 1, 2024
Study Completion (Anticipated)
February 1, 2025
Study Registration Dates
First Submitted
January 18, 2023
First Submitted That Met QC Criteria
April 2, 2023
First Posted (Actual)
April 5, 2023
Study Record Updates
Last Update Posted (Actual)
April 5, 2023
Last Update Submitted That Met QC Criteria
April 2, 2023
Last Verified
April 1, 2023
More Information
Terms related to this study
Keywords
Additional Relevant MeSH Terms
Other Study ID Numbers
- neoRT-Lung
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
NO
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
No
Studies a U.S. FDA-regulated device product
No
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on NSCLC
-
Shanghai Henlius BiotechCompleted
-
The Netherlands Cancer InstituteEnrolling by invitation
-
Centre Oscar LambretUniversity Hospital, LilleTerminated
-
Suzhou Zelgen Biopharmaceuticals Co.,LtdCompleted
-
Bio-Thera SolutionsCompleted
-
Jiangsu Province Nanjing Brain HospitalRecruiting
-
TYK Medicines, IncRecruiting
-
Radboud University Medical CenterPfizer; ImaginAb, Inc.; University Hospital TuebingenNot yet recruitingNSCLCGermany, Netherlands
-
Beta Pharma, Inc.Completed
Clinical Trials on SBRT+LDRT
-
Soonchunhyang University HospitalSMG-SNU Boramae Medical CenterNot yet recruitingNeoplasms | Secondary Malignant Neoplasm
-
Soonchunhyang University HospitalSeoul National University Hospital; SMG-SNU Boramae Medical Center; Saint Vincent... and other collaboratorsRecruitingNeoplasms | Secondary Malignant NeoplasmKorea, Republic of
-
Sichuan UniversityInnovent Biologics (Suzhou) Co. Ltd.Completed
-
Sun Yat-sen UniversityNot yet recruitingNasopharyngeal CarcinomaChina
-
Centro di Riferimento Oncologico - AvianoUnknown
-
Sichuan UniversityRecruitingNSCLC | PD-1 Inhibitor | Stereotactic Body Radiotherapy | Low Dose RadiotherapyChina
-
Sichuan UniversityNot yet recruiting
-
Fudan UniversityNot yet recruiting
-
Wuhan UniversityRecruiting
-
Jinling Hospital, ChinaRecruitingRenal Cell Carcinoma | Radiotherapy | Immune Checkpoint InhibitorChina